Topic: neurological disorders
Coda Biotherapeutics' goal is to create a gene therapy that can be switched on and off, and dialed up and down.
Scrutinizing a newly discovered neuron could help guide efforts to find treatments for neurological diseases.
The brain's lymphatic vessels might play a critical role in Alzheimer's and could be a new target for treatment.
Blocking a pathway that causes healing cells to turn bad could offer a new way to treat neurological disorders.
Celgene launched a $60 million collaboration with Skyhawk Therapeutics to develop small molecules targeting RNA mis-splicing in neurological diseases.
Biogen is paying a $375 million fee and splurging $625 million on Ionis’ stock for a chance to pick up a series of neurological antisense drugs.
Roche snapped up a remyelinating drug candidate for multiple sclerosis from an alliance with Versant that also spawned startup Pipeline Therapeutics.
Perennial biotech dealmaker Takeda is at it again, striking a new pact with Wave Life Sciences with a focus on a series of neurological disorders.
Syndesi begins life with a $20.9 million infusion, to carry a SV2A modulator through early proof of concept.
Biogen is paying $10 million upfront and committing to up to $207 million more in milestones to buy the IND-ready oral SINE compound.